Becton Dickinson Lifts EPS Outlook Amid Mixed Headwinds

Becton, Dickinson and Co ((BDX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Becton, Dickinson and Co’s latest earnings call struck an overall upbeat tone, with management highlighting steady revenue growth, resilient margins and robust cash generation despite a slate of near-term headwinds. Executives emphasized that broad-based execution and high-growth platforms are reinforcing confidence in the “New BD” strategy, even as they acknowledged pressures from tariffs, China, vaccines and specific product issues.

Revenue Growth and Top-Line Performance

BD reported second-quarter revenue of $4.7 billion, up 2.6% year over year on a currency-neutral basis and in line with its low single-digit growth algorithm. Management reaffirmed full-year revenue guidance and said second-half growth should track roughly in line with the first half, suggesting a steady but not spectacular top-line trajectory.

Adjusted EPS and Margin Outperformance

Adjusted EPS reached $2.90 in the quarter, up 3.9% from a year ago and ahead of internal expectations, underscoring earnings resilience. Adjusted operating margin came in at 24.2% and adjusted gross margin at 54.7%, both reflecting solid profitability even as tariffs and investment spending weighed on year-on-year comparisons.

Raised Full-Year Adjusted EPS Guidance

On the back of stronger-than-expected performance in the first half, BD raised its full-year adjusted EPS outlook to a range of $12.52 to $12.72. Management cited improved visibility into the rest of the year and confidence in ongoing productivity gains as key drivers of the higher profit guide.

Broad-Based Portfolio Momentum

More than 90% of BD’s portfolio delivered mid-single-digit growth, demonstrating the breadth of its underlying demand base. Several high-growth platforms posted double-digit gains, including biologic drug delivery, Advanced Patient Monitoring, PureWick and Advanced Tissue Regeneration, which are increasingly central to the company’s growth narrative.

Segment-Level Strengths Across the Franchise

Connected Care grew 3.3%, led by about 12% growth in Advanced Patient Monitoring driven by U.S. consumables demand, while Interventional posted 5.3% growth and Medical Essentials rose 1.7%. Infusion sets within MM&S achieved low double-digit growth, and management highlighted a favorable mix shift within BioPharma Systems that is increasingly skewed toward biologics.

Biologics Momentum and GLP-1 Wins

Biologics now account for roughly 55% of BioPharma Systems revenue, up from about 50% previously, reflecting an accelerating pivot toward higher-value therapies. BD secured several significant long-term biologics contracts, including two next-generation GLP-1 programs with major global pharmaceutical companies, underpinning a multi-year growth runway.

Operational Productivity and BD Excellence

The BD Excellence program continued to be a major performance lever, delivering roughly 8% productivity in the quarter and service levels above 90%. Management noted the initiative is driving around 2,000 Kaizens annually and has cut average time-to-launch by more than 10 months across five development programs this year, boosting both margins and innovation speed.

Cash Generation and Capital Return

Year to date, BD generated $1.1 billion in free cash flow, a significant improvement versus the prior year and a key source of financial flexibility. The company returned about $2.3 billion to shareholders in the quarter through roughly $2.0 billion of share repurchases and $0.3 billion of dividends, while also retiring $2.1 billion of debt to bring net leverage to about 2.9 times.

Cost-Out Progress and Manufacturing Rationalization

BD reported solid progress on its $200 million cost-out program, with a $150 million run-rate already achieved, supporting margin expansion efforts. The company has reduced its manufacturing footprint to around 50 sites and continues to simplify its network, signaling further structural savings and operational efficiency ahead.

Commercial Traction and New Product Launches

Commercial momentum remained strong, with Alaris gaining roughly 50 basis points of share in Q2 and about 150 basis points year to date, and HemoSphere Alta seeing robust adoption alongside about 20% growth in Smart Recovery consumables. New offerings such as Pyxis Pro, EnCor EnCompass, Revello Vascular Covered Stent in Europe, HemoSphere Stream Module, Surgiphor Pulse and Avitene Flowable are expanding BD’s competitive toolkit.

Alaris Headwind and Upgrade Cycle Comparisons

Despite share gains, management flagged Alaris as a known headwind, expecting about 100 basis points of negative revenue impact this fiscal year and up to 200 basis points by FY27 as tough comparisons from a remediation-driven upgrade cycle kick in. Investors were reminded that the recent surge in upgrade-related sales will create a more challenging baseline for future growth in this franchise.

Vaccine Demand Weakness in BioPharma Systems

Within BioPharma Systems, revenue declined 1.8% in the quarter as significantly lower vaccine demand offset the strength in biologics. Management pointed to an industry-wide drop in vaccine volumes this year, highlighting that this softness is cyclical in nature but meaningful enough to dampen segment-level growth in the near term.

Persistent China Market Pressure

China remained a drag on results, with adverse market dynamics continuing to pressure revenue and profitability in the region. The company noted that China now represents around 4% of New BD revenue and may shrink further, and it expects the softness there to persist as a near-term headwind rather than a quick recoverable dip.

Tariffs and Growth Investments Weigh on Margins

Adjusted gross margin declined about 90 basis points year over year and adjusted operating margin fell roughly 110 basis points, with tariffs alone accounting for around 160 basis points of margin pressure. These headwinds were partially offset by about 70 basis points of productivity and mix benefits, while increased commercial investments in growth areas also contributed to the short-term margin compression.

Noncash Impairment Charges and Portfolio Simplification

BD recorded approximately $450 million of noncash impairment charges tied to exiting activities that no longer fit the New BD strategy, reinforcing management’s focus on portfolio discipline. While these charges are excluded from adjusted EPS, they underscore ongoing restructuring and simplification efforts designed to sharpen the company’s long-term growth and margin profile.

FDA Warning Letter and Temporary Product Ship Hold

An FDA warning letter related to BD’s El Paso facility, which manufactures ChloraPrep and PurPrep, led the company to voluntarily pause U.S. shipments while it performs additional final-release testing expected to last around three weeks. Management stressed that production continues and no patient safety concerns have been identified, but acknowledged that the shipment hold represents a short-term revenue risk for its surgical and medical products.

Forward-Looking Guidance and Outlook

Looking ahead, BD reaffirmed its outlook for low single-digit revenue growth for the full year and expects second-half revenue trends to mirror the first half, with currency providing about a 120 basis-point tailwind. The company now projects adjusted EPS between $12.52 and $12.72, an adjusted operating margin near 25% even including tariffs, and an adjusted effective tax rate of 16% to 17%, signaling confidence in continued margin discipline and earnings growth.

BD’s latest earnings call painted the picture of a company balancing solid execution and portfolio momentum with clear-eyed recognition of its near-term challenges. For investors, the message was that strong cash generation, productivity gains and targeted growth investments are more than offsetting macro pressures and specific product issues, supporting an optimistic yet measured outlook for the New BD strategy.